multiple myeloma

News

AstraZeneca has reported an impressive 96% response rate in the DURGA-1 of BCMAxCD19 CAR-T therapy AZD0120 in heavily pretreated multiple myeloma.

News

Kelonia only started human testing of its in vivo CAR-T therapy for multiple myeloma in August, but will report impressive results at ASH next month.

Oncology

Onsite at ESMO 2025 in Berlin, pharmaphorum spoke with Poolbeg's Liam Tremble about their work on CRS in relapsed/refractory multiple myeloma.

News

Against the odds, GSK has secured FDA approval for its multiple myeloma therapy Blenrep, three years after it was removed from sale.

News

Bristol Myers Squibb has said it hopes to be ready soon to file for approval of its multiple myeloma drug iberdomide after a positive phase 3 trial.

News

Johnson & Johnson’s Janssen-Cilag has secured European Commission approval for a new indication of its subcutaneous formulation of DARZALEX